Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
This research investigates participant satisfaction with subcutaneous SC ocrelizumab treatment in people with Multiple Sclerosis MS. It focuses on measuring satisfaction after 12 months of therapy using a specialized questionnaire called the Therapy Administration Satisfaction Questionnaire Subcutaneous TASQ-SC. The study also examines changes and correlations in neurofilament light chain NfL protein levels, a marker related to MS disease activity. Participants who are receiving ocrelizumab SC injections for the first time as part of their routine MS treatment will be observed for up to 12 months. The treatment is given according to the physicians discretion and local clinical practice. Throughout the study, participant satisfaction with the SC injection will be assessed at baseline, 6 months, and 12 months. Blood samples will be collected at these time points to measure NfL protein levels and analyze their relationship to MS relapses, disability scores, prior therapies, and other health factors. During the study, participants will complete satisfaction questionnaires and undergo blood tests at scheduled visits. Researchers will monitor adverse events and track various health indicators including MRI lesion counts and other biomarkers. The main outcome is participant satisfaction at 12 months, with additional assessments at earlier time points. This observational study lasts up to one year, with ongoing collection of safety and disease activity data during that time.
Actively Recruiting
Researchers are evaluating the effects of cold water hydrotherapy on patients with Post-COVID Syndrome, a condition where symptoms like fatigue, autonomic imbalance, and inflammation persist after COVID-19 infection. The study aims to compare quality of life improvements between those receiving hydrotherapy and those receiving usual care without it. The trial is a randomized controlled study sponsored by Eggensberger OHG. Participants in the experimental group will undergo cold water hydrotherapy sessions lasting 5 to 10 minutes, four times daily during a 3-week program, followed by once daily sessions during a 6-month follow-up. The hydrotherapy involves tailored techniques such as washing and pouring. The control group will receive usual care at home without hydrotherapy. Standard medical care is also provided during the 3-week stay for the treatment group. Participants will provide demographic and health data at baseline, including symptoms, smoking history, and prior COVID-19 illness severity. They will undergo autonomic function testing and report work ability and sick leave days. Researchers will monitor quality of life, fatigue, sleep quality, autonomic function, blood pressure, adherence to hydrotherapy, and adverse events over the 6-month period. Daily well-being and post-exertional malaise will also be documented to assess long-term effects.